Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 t-haNK + nogapendekin alfa inbakicept
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
CD19 t-haNK + nogapendekin alfa inbakicept is a combination immunotherapy consisting of an off-the-shelf, CD19-targeted natural killer (NK) cell therapy and an IL-15 superagonist. CD19 t-haNK is derived from the NK-92 cell line, engineered to express a chimeric antigen receptor (CAR) targeting CD19 and a high-affinity CD16 (V158) receptor to enhance antibody-dependent cellular cytotoxicity (ADCC). Nogapendekin alfa inbakicept (N-803) is an IL-15 superagonist complex designed to promote the proliferation and activation of NK cells and T cells without stimulating regulatory T cells. The combination is primarily being investigated for the treatment of relapsed or refractory CD19-positive B-cell non-Hodgkin lymphomas.
- Other names
- CD19 t-haNK + N-803CD19 t-haNK + NAI
02
Targets
CD19 (B lymphocyte antigen CD19)IL-2/15Rβγ (Interleukin-2/interleukin-15 receptor beta/gamma)
Beyond the preview
Go deeper on CD19 t-haNK + nogapendekin alfa inbakicept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 t-haNK + nogapendekin alfa inbakicept.